We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$4.5B
Cap. Flow
% of AUM
10.34%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,819
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$424M |
| 2 |
Kenvue
KVUE
|
+$415M |
| 3 |
Cummins
CMI
|
+$374M |
| 4 |
Bunge Global
BG
|
+$310M |
| 5 |
Newell Brands
NWL
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$423M |
| 2 |
Qualcomm
QCOM
|
+$413M |
| 3 |
D.R. Horton
DHI
|
+$401M |
| 4 |
Booking.com
BKNG
|
+$397M |
| 5 |
Phillips 66
PSX
|
+$389M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 12.39% |
| 4 | Healthcare | 10.91% |
| 5 | Technology | 10.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Denali Therapeutics
DNLI
$3.82B
| $41.6K | ﹤0.01% |
+2,025
| New | +$38.1K |
|
1277
Syndax Pharmaceuticals
SNDX
$1.74B
| $41.3K | ﹤0.01% |
+1,734
| New | +$38.7K |
|
|
ACLX
1278
DELISTED
Arcellx
ACLX
| $41.2K | ﹤0.01% |
+593
| New | +$37.6K |
|
1279
Rocket Pharmaceuticals
RCKT
$343M
| $41.2K | ﹤0.01% |
+1,528
| New | +$43.4K |
|
|
SWTX
1280
DELISTED
SpringWorks Therapeutics
SWTX
| $41K | ﹤0.01% |
+834
| New | +$38.6K |
|
1281
IDEAYA Biosciences
IDYA
$3.48B
| $41K | ﹤0.01% |
+935
| New | +$40.2K |
|
|
FOLD
1282
DELISTED
Amicus Therapeutics
FOLD
| $40.9K | ﹤0.01% |
+3,468
| New | +$44.4K |
|
1283
Marathon Digital Holdings
MARA
$4.34B
| $40.7K | ﹤0.01% |
+1,803
| New | +$39.4K |
|
|
APLS
1284
DELISTED
Apellis Pharmaceuticals
APLS
| $40.7K | ﹤0.01% |
+692
| New | +$44.1K |
|
1285
Biohaven
BHVN
$2.07B
| $40.3K | ﹤0.01% |
+737
| New | +$36.5K |
|
1286
Iovance Biotherapeutics
IOVA
$2.1B
| $40.3K | ﹤0.01% |
+2,716
| New | +$31.6K |
|
1287
Vaxcyte
PCVX
$7.88B
| $40.2K | ﹤0.01% |
+589
| New | +$40.8K |
|
|
SMAR
1288
DELISTED
Smartsheet Inc.
SMAR
| $40K | ﹤0.01% |
1,039
-31
| -3% | -$1.35K |
|
1289
PTC Therapeutics
PTCT
$6.25B
| $39.8K | ﹤0.01% |
+1,367
| New | +$38.3K |
|
1290
Kymera Therapeutics
KYMR
$8.73B
| $39.4K | ﹤0.01% |
+981
| New | +$35.1K |
|
1291
Intellia Therapeutics
NTLA
$1.52B
| $39.3K | ﹤0.01% |
+1,427
| New | +$39.6K |
|
1292
Ultragenyx Pharmaceutical
RARE
$2.56B
| $39.2K | ﹤0.01% |
+840
| New | +$39.6K |
|
1293
Simulations Plus
SLP
$371M
| $39.2K | ﹤0.01% |
953
+458
| +93% | +$18.8K |
|
1294
Twist Bioscience
TWST
$5.51B
| $39K | ﹤0.01% |
+1,138
| New | +$41.1K |
|
1295
TG Therapeutics
TGTX
$8.4B
| $38.7K | ﹤0.01% |
+2,542
| New | +$40.5K |
|
1296
Arcutis Biotherapeutics
ARQT
$3.55B
| $38.4K | ﹤0.01% |
+3,875
| New | +$28.9K |
|
|
NNDM
1297
Nano Dimension
NNDM
$314M
| $38.3K | ﹤0.01% |
13,751
-18
| -0.1% | -$46 |
|
1298
Recursion Pharmaceuticals
RXRX
$1.62B
| $38K | ﹤0.01% |
+3,812
| New | +$42.5K |
|
1299
Stratasys
SSYS
$690M
| $37.6K | ﹤0.01% |
3,238
-3
| -0.1% | -$38 |
|
|
NUVL
1300
DELISTED
Nuvalent
NUVL
| $37.6K | ﹤0.01% |
+501
| New | +$39.9K |
|
Similar funds
SAM
Pacer Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Pacer Advisors held 3,819 positions worth $43.5B, up 23% from $35.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Pacer Advisors deployed $4.5B of net new capital in Q1 2024, opening 249 new positions and adding to 1,063 existing holdings. Its largest new stake was Hanesbrands: 32,772,533 shares worth $190M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 19% a quarter earlier, followed by Energy and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $423M trimmed.
- Pacer Advisors's largest Q1 2024 buy was Hanesbrands: 32,772,533 shares worth $190M.
- Pacer Advisors added most to AT&T in Q1 2024, an estimated $424M increase.
- Pacer Advisors's biggest Q1 2024 reduction was AbbVie, cutting an estimated $423M.
- Pacer Advisors fully exited Tri Pointe Homes in Q1 2024, selling an estimated $139M.
- Pacer Advisors's ten largest holdings make up 12% of its $43.5B portfolio in Q1 2024.
- Pacer Advisors opened 249 new positions and closed 119 in Q1 2024.
- Pacer Advisors's portfolio value rose 23% quarter-over-quarter to $43.5B.
Based on Pacer Advisors's 13F filing for Q1 2024, filed 10 May 2024.